A new publication involving pasireotide appeared on August 5, 2026. The paper, titled "Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System," was published in Frontiers in Endocrinology.
The publication addresses pasireotide's use as a second-line treatment option for adult patients with acromegaly. It evaluates this use specifically from the perspective of the Brazilian Unified Health System.
This entry reflects the publication of the study itself, not its findings or conclusions. No specific results, cost figures, or outcome data from the study are included here.
Pasireotide remains an approved therapy. Readers interested in additional details about this specific analysis are encouraged to consult the full publication directly through the source listed below.
For general background on pasireotide, including its approved indications and regulatory history, see the compound overview.